Odoribacter splanchnicus rescues aging-related intestinal P-glycoprotein damage via GDP-L-fucose secretion

  • Nat Commun. 2025 Nov 27;16(1):10665. doi: 10.1038/s41467-025-65692-1.
Cheng Cui  #  1  2 ,  Lu Fang  #  3  4  5 ,  Lei Li  #  4  6  7 ,  Xuan Lai  8 ,  Ruitao Zhang  4  6  7 ,  Qi Zhang  3  4 ,  Rong Miao  3  4 ,  Gaofei Hu  3  4 ,  Miao Zhang  1  2 ,  Jie En Valerie Sia  1  2 ,  Jingcheng Chen  1  2 ,  Haodi Chai  1  2 ,  Xinyi Wu  1  2 ,  Zijin Lin  1  2 ,  Fan Zhang  8 ,  Haiyan Li  4  6  7 ,  Lemin Zheng  9  10  11 ,  Dongyang Liu  12  13  14  15
Affiliations
  • 1. Drug Clinical Trial Center, Department of Pharmacy, Peking University Third Hospital, Beijing, China.
  • 2. Center of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
  • 3. The Institute of Cardiovascular Sciences, the Institute of Systems Biomedicine, School of Basic Medical Sciences, Health Science Center, Peking University, Beijing, China.
  • 4. State Key Laboratory of Vascular Homeostasis and Remodeling, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Peking University, Beijing, China.
  • 5. Research Center for Cardiopulmonary Rehabilitation, University of Health and Rehabilitation Sciences Qingdao Hospital (Qingdao Municipal Hospital), School of Health and Life Sciences, University of Health and Rehabilitation Sciences, Qingdao, China.
  • 6. Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University Third Hospital, Beijing, China.
  • 7. Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China.
  • 8. Geriatrics Department, Peking University Third Hospital, Beijing, China.
  • 9. The Institute of Cardiovascular Sciences, the Institute of Systems Biomedicine, School of Basic Medical Sciences, Health Science Center, Peking University, Beijing, China. [email protected].
  • 10. State Key Laboratory of Vascular Homeostasis and Remodeling, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Peking University, Beijing, China. [email protected].
  • 11. Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases, Advanced Innovation Center for Human Brain Protection, The Capital Medical University, Beijing, China. [email protected].
  • 12. Drug Clinical Trial Center, Department of Pharmacy, Peking University Third Hospital, Beijing, China. [email protected].
  • 13. Center of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China. [email protected].
  • 14. State Key Laboratory of Vascular Homeostasis and Remodeling, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Peking University, Beijing, China. [email protected].
  • 15. Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University Third Hospital, Beijing, China. [email protected].
  • # Contributed equally.
Abstract

Intestinal P-glycoprotein (P-gp/ABCB1) is a key barrier limiting xenobiotic absorption, yet its functional decline with aging is poorly understood. Here, we show that gut microbiota dysbiosis contributes to age-associated P-gp deficiency. Integrated multi-omics analyses of human cohorts and murine models identify Odoribacter splanchnicus (O. splanchnicus) as a key commensal species whose depletion impairs intestinal P-gp function. Mechanistically, O. splanchnicus encodes GDP-mannose 4, 6-dehydratase (GMDS) and GDP-L-fucose synthase (TSTA3), enabling microbial biosynthesis of GDP-L-fucose. This metabolite directly promotes phosphorylation of the eukaryotic translation initiation factor 4E (eIF4E) and activates c-Jun-driven ABCB1 expression, thereby restoring xenobiotic efflux. These findings establish a microbiota-metabolite-transporter signaling axis that maintains intestinal detoxification, suggesting that targeting either microbes or metabolites could help prevent adverse drug reactions in older adults.

Products